Stocks › IBRX

ImmunityBio, Inc.

IBRX·Nasdaq·United States United States·USD
$6.02
-0.55 (-8.37%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
IBRX
ImmunityBio, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
IBRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of IBRX by members of U.S. Congress · 3 on record · 2 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Lisa C. McClainLisa C. McClainHouse · R · MI IBRXImmunityBio, Inc. · Stock Purchase
$1,001 - $15,000
Oct 12, 2026 Sep 30, 2026 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI IBRXImmunityBio, Inc. · Stock Purchase
$1,001 - $15,000
Oct 12, 2026 Sep 28, 2026 Filing ↗
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY IBRXImmunityBio, Inc. · Stock Sale
$1,001 - $15,000
Apr 17, 2023 Mar 6, 2023 Filing ↗

Whale Activity

Position changes in IBRX reported for 2026-09-30 by 456 institutional filers
Increased: 146New: 48Held: 96Decreased: 95Closed: 47No prior filing: 24
  • Increased146
  • New48
  • Held96
  • Decreased95
  • Closed47
  • No prior filing24
FilerSharesValueChange
BlackRock, Inc.36.1M$341.0Mincreased
STATE STREET CORP21.1M$199.1Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC19.4M$183.0Mincreased
VANGUARD CAPITAL MANAGEMENT LLC18.8M$177.5Mincreased
D. E. Shaw & Co., Inc.10.7M$101.1Mdecreased
GEODE CAPITAL MANAGEMENT, LLC10.6M$100.1Mincreased
TWO SIGMA INVESTMENTS, LP5.8M$55.0Mdecreased
CHARLES SCHWAB INVESTMENT MANAGEMENT INC4.9M$46.6Mincreased
GOLDMAN SACHS GROUP INC4.1M$39.0Mincreased
MILLENNIUM MANAGEMENT LLC3.8M$36.0Mdecreased
UBS Group AG3.8M$35.6Mincreased
NORTHERN TRUST CORP3.7M$34.9Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by IBRX insiders, by quarter · Form 4
-1.0M-500.0K0500.0K1.0M2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: -502.0K2026 Q12026 Q2: -144.8K2026 Q22026 Q3: -290.7K2026 Q32026 Q4: -106.1K2026 Q4

Recent Insider Transactions

124 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Simon Barry J.Director · Director Sale −25.0K $10.75 $269K Oct 5, 2026 Form 4 ↗
Cohen CherylDirector · Director Sale −81.1K $10.50 $851K Oct 2, 2026 Form 4 ↗
Cohen CherylDirector Sale −131.2K $9.50 $1.2M Jul 2, 2026 Form 4 ↗
Cohen CherylDirector Option exercise +56.0K $2.98 $167K Jul 2, 2026 Form 4 ↗
Selecky ChristobelDirector Sale −159.5K $9.02 $1.4M Jul 1, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +124.4K $2.99 $372K Jul 1, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +35.1K $2.98 $104K Jul 1, 2026 Form 4 ↗
Selecky ChristobelDirector Sale −1,000 $9.00 $9K Jun 30, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +300 $2.99 $897 Jun 30, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +700 $2.98 $2K Jun 30, 2026 Form 4 ↗
Selecky ChristobelDirector Sale −95.7K $9.01 $862K Jun 29, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +30.0K $2.84 $85K Jun 29, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +33.5K $2.99 $100K Jun 29, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +32.2K $2.98 $96K Jun 29, 2026 Form 4 ↗
Simon Barry J.Director Sale −25.0K $7.88 $197K Jun 24, 2026 Form 4 ↗
Simon Barry J.Director Sale −23.0K $7.18 $165K Jun 4, 2026 Form 4 ↗
CALIFORNIA CAPITAL EQUITY, LLC10% owner Conversion +4.6M $5.43 $25.0M Mar 31, 2026 Form 4 ↗
Simon Barry J.Director Sale −75.0K $12.01 $901K Feb 24, 2026 Form 4 ↗
Selecky ChristobelDirector Sale −25.0K $10.00 $250K Feb 23, 2026 Form 4 ↗
Selecky ChristobelDirector Option exercise +25.0K $2.98 $75K Feb 23, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding IBRX · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
12.5M$109.4M1.02%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
11.6M$101.5M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
9.9M$86.9M0.10%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
8.4M$73.5M0.04%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
4.9M$42.5M0.09%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.7M$32.6M0.03%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
3.6M$31.2M0.20%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
4.2M$30.3M0.09%Jul 31, 2026
iShares Biotechnology ETF
iShares Trust
2.7M$23.3M0.26%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
2.2M$17.6M0.10%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list IBRX's shares (CUSIP 45256X103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Patrick Soon-ShiongSCHEDULE 13D/A · activist (13D) · 745.5M shares64.8%
    Aug 6, 2026 · ↗
  • California Capital Equity, LLCSCHEDULE 13D/A · activist (13D) · 106.5M shares10.0%
    Aug 6, 2026 · ↗
  • Nant Capital, LLCSCHEDULE 13D/A · activist (13D) · 339.5M shares29.6%
    Aug 6, 2026 · ↗
  • NantWorks, LLCSCHEDULE 13D/A · activist (13D) · 98.5M shares9.3%
    Aug 6, 2026 · ↗
  • MP 13 Ventures, LLCSCHEDULE 13D/A · activist (13D) · 261.7M shares24.7%
    Aug 6, 2026 · ↗
  • Cambridge Equities, LPSCHEDULE 13D/A · activist (13D) · 261.7M shares24.7%
    Aug 6, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming immunitybio as client
$0$25K$50K$75K$100K2025 Q4: $60K20252026 Q1: $60K2026
  • CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2026 Q2—
    Filing ↗
  • CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2026 Q1$60K
    Filing ↗
  • CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2025 Q4 · HCR$60K
    Filing ↗
  • CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2025 Q4 · MED, HCR—
    Filing ↗
  • THE PETRIZZO GROUP, INC.IMMUNITYBIO, INC. · 2022 Q3 · MED, HCR$45K
    Filing ↗

Government Contracts

Federal awards to ImmunityBio, Inc. · USAspending

No federal contract awards found for ImmunityBio, Inc..

U.S. Patents

Recent USPTO applications naming ImmunityBio, Inc.

No USPTO patent applications found for ImmunityBio, Inc..

Annual Financials

From IBRX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$113.3M$14.7M$622K$240K$934K
Operating income-$256.0M-$344.2M-$362.3M-$351.3M-$330.3M
Net income-$351.4M-$413.6M-$583.2M-$416.6M-$346.8M
Diluted EPS-$0.38-$0.62-$1.15-$1.04-$0.89
Operating cash flow-$304.9M-$391.2M-$366.8M-$337.5M-$274.4M
Cash and equivalents$88.3M$143.4M$265.5M$104.6M$181.1M
Total assets$501.9M$382.9M$504.5M$362.4M$468.9M
Total liabilities$1.00B$871.1M$1.09B$812.2M$712.8M
Shareholders' equity-$500.5M-$489.1M-$587.0M-$447.3M-$242.2M

As ImmunityBio, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 23, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in IBRX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureNov 9, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureOct 14, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureJul 30, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 9.01Shareholder voteJun 10, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureMay 18, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
    EDGAR ↗

About ImmunityBio, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
Former namesNantKwest, Inc., Conkwest, Inc., ZelleRx Corp